Description
Profhilo H+L Facial Treatment for Hydration and Facial Lifting
PROFHILO® H+L is a class of injectable medical-device gel comprising ultra-pure hyaluronic acid (HA) sodium salt in a high-concentration “hybrid cooperative complex” format combining high-molecular-weight (H-HA) and low-molecular-weight (L-HA) chains via the patented NAHYCO® technology. The product is indicated primarily for the treatment of facial skin laxity – for example the malar-zygomatic and sub-malar regions – and for the re-definition of contours and remodelling of lax tissue.
The gel is non–chemically cross-linked (i.e., no BDDE) and designed to diffuse within the dermal and sub-cutaneous layers to support hydration, restructure the extracellular matrix, and promote a corrective effect in photo- and chrono-aged skin.
What PROFHILO® H+L Is Similar To
PROFHILO® H+L can be regarded alongside other skin-booster or bioremodelling injectables such as Sunekos® or Rejuran®, in that all aim to improve skin architecture rather than provide significant volumetric augmentation. For example, Sunekos® uses amino-acid and peptide complexes to stimulate collagen and elastin, while PROFHILO uses HA hybrid complexes for hydration and matrix stimulation. However, unlike many traditional dermal fillers (e.g., HA volumisers such as Juvederm® or Restylane®) which are designed to restore volume or fill wrinkles, PROFHILO® H+L emphasises tissue remodelling and hydration over lifting or bulk augmentation. Its longevity is also distinct: after a primary two-session protocol it is reported to last around six months in many cases , whereas volumising HA fillers may last 9–18 months depending on cross-linking and location. This comparison is provided for clinical orientation only and does not imply interchangeability.
Treatment Areas / Indications
According to manufacturer documentation, PROFHILO® is indicated for the face and body for contour re-definition and laxity remodelling; in particular the malar-zygomatic, sub-malar, brachial (arm) and abdominal areas.
Treatment areas: Face (malar & sub-malar) • Body (arms, abdomen, brachial)
→ For PROFHILO® H+L specifically, the IFU emphasises treatment of facial skin laxity (malar-zygomatic and sub-malar regions) and states use on the body where indicated.
Usage / Administration
Injection depth: Deep dermal/sub-cutaneous bolus.
Volume per point / injection site: 0.2 mL per injection site.
Needle gauge: 29 G × ½” (0.33 × 12 mm) is supplied with syringe.
Frequency / number of sessions: Initial cycle of two treatment sessions at 30-day (approximately) intervals; maintenance treatments every 2 months if necessary.
Ingredient List
-
Hyaluronic acid sodium salt: 32 mg high-molecular-weight HA (H-HA) + 32 mg low-molecular-weight HA (L-HA) per 2 mL syringe.
-
Sodium chloride
-
Sodium phosphate
-
Water for injection
Lidocaine: Not provided by manufacturer.
Other excipients as per IFU; additional trace components not disclosed.
Presentation & Longevity
Presentation: 1 × 2 mL pre-filled sterile syringe, supplied with 2 × 29 G × ½” needles (0.33 × 12 mm)
Longevity (treatment duration): The effects are typically reported to last about six months after the initial two-session protocol, although individual results may vary depending on patient age, anatomy and injection technique.
Safety Notes / Contraindications
-
Use is contraindicated in patients with known hypersensitivity to any component of the product.
-
Avoid in patients with active skin infections or inflammation at the injection site (e.g., cysts, pimples, rashes) until condition is resolved.
-
Do not inject intravenously, into muscles, tendons or for mammary (breast) augmentation.
-
Single use only; do not reuse syringe; ensure packaging intact and within expiry.
Regulatory Status
CE-marked medical device (CE 0197) in Europe.
UKCA status: verify via IFU or distributor.
Regulatory classification not fully specified in public documentation for all jurisdictions; verify on the product pack or manufacturer’s IFU.
FAQ
1. How does PROFHILO® H+L work in the skin?
PROFHILO® H+L uses a hybrid complex of low- and high-molecular-weight HA which, once injected into the deep dermal/sub-cutaneous layer, spreads via the BAP (Bio Aesthetic Points) technique and diffuses across the tissue. Its mechanism is described as “bioremodelling” the low-MW HA contributes immediate hydration, while the high-MW HA supports dermal scaffold integrity and stimulates fibroblasts to synthesize new collagen and elastin.
2. Is PROFHILO® H+L the same as a traditional dermal filler?
No. Unlike volumising HA fillers that are designed to fill wrinkles or restore volume (via thicker gels, higher cross-linking), PROFHILO® H+L is formulated for tissue remodelling and skin quality improvement rather than structural augmentation. It uses non-cross-linked HA in a spreadable form and fewer injection sites, focusing on hydration, laxity and skin tone.
3. What is the typical treatment protocol and how long do the results last?
The standard protocol involves two sessions spaced approximately 30 days apart; after the initial cycle, maintenance treatments may be administered every two months if required. Clinical reports suggest the effect lasts around six months, though this varies with patient factors and injection technique.
4. Can PROFHILO® H+L be used on areas beyond the face?
Yes manufacturer documentation includes body areas such as brachial (arms) and abdomen for contour re-definition and skin laxity remodelling. However, practitioners should verify local regulatory indications and patient suitability for off-label uses.
5. What safety considerations should practitioners keep in mind?
As with all injectable devices, strict aseptic technique, knowledge of anatomy and patient medical history are essential. Because the product diffuses widely, care must be taken to avoid off-target injection or intravascular placement. Contraindications include active skin infection, severe allergies, bleeding disorders. Post-treatment, patients should avoid strong UV exposure and protect treated areas with sun-block for a few days.
